The RESORCE trial was a pivotal Phase 3 trial evaluating the efficacy and safety of regorafenib as second-line systemic therapy in patients with advanced HCC.
Post-hoc analysis of this trial has been conducted by Dr Richard Finn and colleagues, which revealed that regorafenib provided benefit regardless of disease progression during prior sorafenib treatment.
Chaired by Professor Josep Llovet and featuring guest author Dr Richard Finn, this session explores the available data surrounding systemic treatment sequencing, and how this should impact your practice.
If you would like to receive CME credits for watching this video please visit Oncology Knowledge into Practice.
If you scroll down the page you will see a button asking you to complete a short evaluation and claim credit.
If you would like to register for free to receive similar education please visit www.onkip.com.
This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals.
The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.
If you are from the UK, France or Italy and want to listen to advice from experts from your country please visit Oncology knowledge into practice.